AbbVie Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Robert A. Michael
- Full Time Employees
- 57,000
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 1 North Waukegan Road North Chicago IL United States of America 60064-6400
- IPO Date
- Jan 2, 2013
- CIK
- 0001551152
- Website
- abbvie.com
- Similar Companies
- Business
- AbbVie Inc. (NYSE: ABBV) is a global research-based biopharmaceutical company that discovers, develops, manufactures and commercializes innovative medicines across immunology, oncology, neuroscience, eye care, aesthetics, virology and gastroenterology. Founded in 2013 as a spin-off from Abbott Laboratories and headquartered in North Chicago, Illinois, the company operates in more than 70 countries with approximately 55,000 employees worldwide. Its core products include Humira (adalimumab) for autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, Crohn's disease and ulcerative colitis; Skyrizi (risankizumab) and Rinvoq (upadacitinib), both interleukin inhibitors for immunology indications; Imbruvica (ibrutinib) and Venclexta (venetoclax) for oncology; Vraylar (cariprazine) for schizophrenia and bipolar disorder; Botox for aesthetics; Mavyret (glecaprevir/pibrentasvir) for hepatitis C; and Epkinly (epcoritamab) for blood cancers, among others including Duopa/Duodopa, Ubrelvy and Vyalev in neuroscience and pipeline candidates for Parkinson's disease. AbbVie markets its portfolio to patients, healthcare providers and health systems globally, with major revenue contributions from the United States and international markets. In recent developments, the company completed acquisitions of ImmunoGen for $10.1 billion in 2024 to bolster ovarian cancer treatments with Elahere, Cerevel Therapeutics for $8.7 billion to expand neuroscience, Aliada Therapeutics for $1.4 billion, Nimble Therapeutics and Capstan Therapeutics in 2024-2025 for immunology enhancements, and Gilgamesh Pharmaceuticals in 2025 for a psychiatry drug bretisilocin valued up to $1.2 billion; it also announced partnerships such as $1.64 billion with Neomorph for molecular glue degraders and licensing from Gubra for obesity treatments, alongside over 30 deals since 2024 and manufacturing expansions including a $195 million API facility and $70 million biologics site in the U.S. to support over $10 billion in domestic investments.
AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
AbbVie: A Dividend Fortress At An Appealing Price Tag
Netflix, AbbVie, Cerebras Systems And An Energy Stock On CNBC's ‘Final Trades'
Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Which Healthcare ETF Is the Better Buy: Vanguard's VHT or Fidelity's FHLC?
I'd Double a Position in These 3 Dividend Stocks Right Now Without Any Hesitation
Which Is the Better Healthcare ETF: First Trust's High-Conviction FBT or Vanguard's Low-Cost VHT?
Which iShares Healthcare ETF Is the Better Buy: Diversified IXJ or Biotech-Focused IBB?
4,373 Shares in AbbVie Inc. $ABBV Acquired by Ascension Capital Advisors Inc.
AR Asset Management Inc. Acquires 2,266 Shares of AbbVie Inc. $ABBV
Will AbbVie's Oncology Franchise Remain Under Pressure in Q2?
PINK vs. IXJ: Which Health Care ETF Is the Better Buy for Investors?
ABN Amro Investment Solutions Buys 105,906 Shares of AbbVie Inc. $ABBV
AbbVie (ABBV) Beats Stock Market Upswing: What Investors Need to Know
3 Reasons to Buy AbbVie Stock Like There's No Tomorrow
IXJ vs. RSPH: Which Healthcare ETF Is the Better Buy?
Which Is the Better Healthcare ETF, First Trust's Biotech-Focused FBT or State Street's Broader XLV?
Baader Bank Aktiengesellschaft Acquires 6,263 Shares of AbbVie Inc. $ABBV
Andra AP fonden Has $61.73 Million Holdings in AbbVie Inc. $ABBV
For Global Pharma Exposure Is the VanEck Pharmaceutical ETF or iShares Healthcare Fund the Better Buy in 2026?